Mitralign has announced the start of its SCOUT II study in Europe; the study is evaluating the company’s Trialign percutaneous system for the treatment of patients with tricuspid regurgitation. The system is currently being investigated in the SCOUT I Early Feasibility Study and in the SCOUT II CE mark study.
Azeem Latib (Raffaele Scientific Institute, Milan, Italy) says: “We are pleased to be the first centre in Europe to commence enrolling in SCOUT II. This is an exciting therapy which allows us to deliver a minimally invasive solution to a group of patients who have limited treatment options. The procedure was a great success, as we saw acute reduction in tricuspid regurgitation and the patient was able to go home shortly thereafter.”
“The tricuspid valve is the last major valve opportunity in the structural heart space. The six-month data from our SCOUT I EFS Study in the USA has provided early safety and efficacy signals that we plan to build on with SCOUT II,” comments Rick Geoffrion, chief executive officer of Mitralign.
